Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 7.

Order by Relevance | Date

Total 546 results found since Jan 2013.

Stroke and Vascular Cognitive Impairment: The Role of Intestinal Microbiota Metabolite TMAO
CNS Neurol Disord Drug Targets. 2023 Feb 3. doi: 10.2174/1871527322666230203140805. Online ahead of print.ABSTRACTThe gut microbiome interacts with the brain bidirectionally through the microbiome-gut-brain axis, which plays a key role in regulating various nervous system pathophysiological processes. Trimethylamine N-oxide (TMAO) is produced by choline metabolism through intestinal microorganisms, which can cross the blood-brain barrier to act on the central nervous system. Previous studies have shown that elevated plasma TMAO concentrations increase the risk of major adverse cardiovascular events, but there are few studi...
Source: CNS and Neurological Disorders Drug Targets - February 6, 2023 Category: Drugs & Pharmacology Authors: Ruxin Tu Jian Xia Source Type: research

The mechanisms of minocycline in alleviating ischemic stroke damage and cerebral ischemia-reperfusion injury
Eur J Pharmacol. 2023 Jul 6:175903. doi: 10.1016/j.ejphar.2023.175903. Online ahead of print.ABSTRACTStroke is a group of diseases resulting from cerebral vascular rupture or obstruction and subsequent brain blood circulation disorder, leading to rapid neurological deficits. Ischemic stroke accounts for the majority of all stroke cases. The current treatments for ischemic stroke mainly include t-PA thrombolytic therapy and surgical thrombectomy. However, these interventions aimed at recanalizing cerebral vessels can paradoxically lead to ischemia-reperfusion injury, which exacerbates the severity of brain damage. Minocycli...
Source: European Journal of Pharmacology - July 8, 2023 Category: Drugs & Pharmacology Authors: Kemeng Zhao Pengwei Wang Xiaoguang Tang Na Chang Haonan Shi Longfei Guo Bingyi Wang Pengfei Yang Tiantian Zhu Xinghua Zhao Source Type: research

Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke.
Abstract Intravenous recombinant human tissue plasminogen activato (rtPA, formulated as alteplase) is the primary therapy for acute ischaemic stroke by breaking down a clot of an occluded vessel. There are several randomised controlled trials and observational studies that support the use of rtPA to improve functional outcome following acute ischaemic stroke. However, thrombolytic therapy with rtPA can be associated with a number of complications. Many of the rtPA-related complications result from its thrombolytic action including bleeding (intracerebral and systemic haemorrhage), reperfusion injury with oedema, a...
Source: CNS and Neurological Disorders Drug Targets - February 4, 2013 Category: Drugs & Pharmacology Authors: Balami JS, Sutherland BA, Buchan AM Tags: CNS Neurol Disord Drug Targets Source Type: research

One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke.
Abstract Tissue plasminogen activator (t-PA) is the only FDA approved drug for acute ischemic stroke treatment, but its clinical use is limited due to the narrow therapeutic time window and severe adverse effects, including hemorrhagic transformation (HT) and neurotoxicity. One of the potential resolutions is to use adjunct therapies to reduce the side effects and extend t-PA's therapeutic time window. However, therapies modulating single target seems not satisfying, and a multi-target strategy is warranted to resolve such complex disease. Recent years, large amounts of efforts have been made to explore the active...
Source: Current Neuropharmacology - December 7, 2015 Category: Drugs & Pharmacology Authors: Chen HS, Qi SH, Shen JG Tags: Curr Neuropharmacol Source Type: research

Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke.
CONCLUSION: The individuals with both the CYP2C19(*)2 allele and hypertension are at high risk of CR during anti-thrombosis therapy. The CYP3A4(*)1G allele, P2RY12 (rs2046934) C allele and NR1I2 (rs13059232) CC genotype may be protective factors for CR. The associated SNPs studied may be useful to predict clopidogrel resistance in Chinese patients with ischemic stroke. PMID: 27133299 [PubMed - as supplied by publisher]
Source: Acta Pharmacologica Sinica - May 1, 2016 Category: Drugs & Pharmacology Authors: Liu R, Zhou ZY, Chen YB, Li JL, Yu WB, Chen XM, Zhao M, Zhao YQ, Cai YF, Jin J, Huang M Tags: Acta Pharmacol Sin Source Type: research

One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke.
Abstract Tissue plasminogen activator (t-PA) is the only FDA approved drug for acute ischemic stroke treatment, but its clinical use is limited due to the narrow therapeutic time window and severe adverse effects, including hemorrhagic transformation (HT) and neurotoxicity. One of the potential resolutions is to use adjunct therapies to reduce the side effects and extend t-PA's therapeutic time window. However, therapies modulating single target seems not satisfying, and a multi-target strategy is warranted to resolve such complex disease. Recent years, large amounts of efforts have been made to explore the active...
Source: Current Neuropharmacology - June 18, 2016 Category: Drugs & Pharmacology Authors: Chen HS, Qi SH, Shen JG Tags: Curr Neuropharmacol Source Type: research

Observation of clinical efficacy of rt-PA intravenous thrombolytic treatment for patients combined with grade 0-1 diabetic foot by Wagner classification and acute ischemic stroke.
CONCLUSIONS: rt-PA can reduce the level serum fibrinogen, promotes local microcirculation and nutrition metabolism of diabetic foot, and improve the clinical prognosis of patients with diabetic foot, but will not increase the incidence of adverse events at the same time. PMID: 28051251 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - January 6, 2017 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Thrombolytic therapies for ischemic stroke: Triumphs and future challenges.
Abstract Acute stroke therapy has significantly evolved over the last two decades. The two main advances have been the approval of intravenous chemical thrombolysis in 1995, and the approval of intra-arterial mechanical thrombectomy in 2015. This has lead to significant improvement of functional outcomes in a disease known to be the first cause of disability worldwide. Subsequent studies have focused on identifying pre-treatment predictors of good treatment candidates, by developing biochemical and imaging biomarkers. Different doses and agents of thrombolysis are also being tested. In this review article, we expl...
Source: Neuropharmacology - March 2, 2018 Category: Drugs & Pharmacology Authors: Moussaddy A, Demchuk AM, Hill MD Tags: Neuropharmacology Source Type: research

Therapeutic Challenges in Patients With Noncardioembolic Acute Ischemic Stroke in Need of Double Antiplatelet Therapy for Coronary Artery Disease
Conclusions: In the acute phase of an IS, maintenance or initiation of DAPT therapy imposed by CHD relies, on one hand, on the risk of hemorrhagic transformation of the brain injury and, on the other hand, on the risk of stent thrombosis in the coronary arteries. The management of these patients must be carried on by a vascular team, on an individualized basis.
Source: American Journal of Therapeutics - March 1, 2019 Category: Drugs & Pharmacology Tags: Systematic Reviews Source Type: research

Analysis of the Association Between Polymorphisms within PAI-1 and ACE genes and Ischemic Stroke Outcome After rt-PA Therapy.
CONCLUSION: Results of our study suggest that stroke patients with ACE II genotype, treated with rt-PA, may be at risk of HT. PMID: 31013014 [PubMed - in process]
Source: Journal of Pharmacy and Pharmaceutical Sciences - April 24, 2019 Category: Drugs & Pharmacology Tags: J Pharm Pharm Sci Source Type: research

Antithrombotic therapy in patients with recent stroke and atrial fibrillation.
Abstract Atrial fibrillation (AF) is a common arrhythmia which carries a significant risk of stroke. Secondary prevention, in particular in the acute phase of stroke with anti-thrombotic therapy has not been validated. The aim of this review is to evaluate the available evidence on the use of antithrombotic therapy in patients with recent stroke who have AF, and suggest a treatment algorithm for the various time points, taking into account both the bleeding and thrombosis risks posed at each stage. PMID: 32264805 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - April 6, 2020 Category: Drugs & Pharmacology Authors: Saberwal B, Ioannou A, Lim WY, Beirne AM, Chow AW, Tousoulis D, Ahsan S, Papageorgiou N Tags: Curr Pharm Des Source Type: research